Anke Rentsch

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
A better understanding of patients’ views on the benefit and burden obtained from palliative chemotherapy would facilitate shared decision making. We evaluated palliative cancer patients’ reported outcomes (PROs) for toxicity and investigated the survival threshold for which they would repeat chemotherapy (CTx). Patients who had received a minimum of three(More)
  • 1